InvestorsHub Logo
Followers 24
Posts 501
Boards Moderated 1
Alias Born 03/09/2014

Re: None

Tuesday, 09/01/2020 7:17:27 AM

Tuesday, September 01, 2020 7:17:27 AM

Post# of 72
Open Access Major ISEE Publication out in #1American Eye Journal Ophthalmology :
“Intravitreal administration of avacincaptad pegol 2 mg and 4 mg led to a significant reduction of GA growth in eyes with AMD over a 12 month period. As C5 inhibition theoretically preserves C3 activity it may offer additional safety advantages. A second confirmatory pivotal clinical trial is underway to confirm the efficacy and safety of avacincaptad pegol in slowing the GA growth (GATHER2 Study).”
Ssfety is key - disqualifies APLS in AMD.

https://www.aaojournal.org/article/S0161-6420(20)30845-9/fulltext?dgcid=raven_jbs_aip_email
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ISEE News